Despite having a high affinity to BCL-2, BCL-XL, and BCL-W [14], the clinical use of navitoclax (ABT-263) has been restricted by the on-target toxicity of thrombocytopenia [115]. The gene discussed is BCL2L1; the disease is Thrombocytopenia.